EXICURE, INC. Operating Lease Liability
EXICURE, INC. (XCUR) had Operating Lease Liability of $5.93 million as of 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2025-03-18
- 2024-12-31: Operating Lease, Liability $5.93M.
- 2023-12-31: Operating Lease, Liability $6.67M.
- 2022-12-31: Operating Lease, Liability $7.31M.
- 2021-12-31: Operating Lease, Liability $7.86M.
| Period end | Operating Lease, Liability |
|---|---|
| 2024-12-31 | $5.93M 10-K · filed 2025-03-18 |
| 2023-12-31 | $6.67M 10-K · filed 2024-06-06 |
| 2022-12-31 | $7.31M 10-K · filed 2023-03-27 |
| 2021-12-31 | $7.86M 10-K · filed 2022-03-25 |
| 2021-09-30 | $7.99M 10-Q · filed 2021-11-19 |
| 2021-06-30 | $8.12M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $8.16M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $8.18M 10-K · filed 2021-03-11 |
| 2020-09-30 | $8.26M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $196.00K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $275.00K 10-Q · filed 2020-05-14 |
| 2019-12-31 | $351.00K 10-K · filed 2020-03-10 |
| 2019-09-30 | $423.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $492.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $559.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |